Literature DB >> 16183525

Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics.

Guido Rindi1, Cesare Bordi.   

Abstract

Endocrine tumours of the gut and pancreas originate from cells of the diffuse endocrine system and are characterised by the production of a wide variety of bioactive substances including growth factors. Two major tumour categories are distinguished-well-differentiated and poorly differentiated neoplasms-with distinct phenotypes and significantly diverse clinical behaviour. Here, genetic background data are summarised on an anatomical basis for tumours of foregut, midgut and hindgut derivatives. For well-differentiated tumours, independent techniques identified the abnormality of multiple chromosomal sites and genes, pointing to a complex genetic background. Differences in foregut tumours compared with midgut and hindgut tumours are, however, outlined. The multiple endocrine neoplasia syndrome type 1 (MEN1) gene is reported to be involved in about one-third of sporadic foregut endocrine tumours and exceptionally in midgut and hindgut tumours. Similarly, X chromosome markers are associated with malignant behaviour in foregut tumours only. For poorly differentiated carcinomas, a high degree of chromosomal instability is the common genetic trait independent of tumour site and frequently involving the p53 gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183525     DOI: 10.1016/j.bpg.2005.03.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  14 in total

1.  Hepatobiliary neuroendocrine carcinoma: a case report.

Authors:  Suzana Manxhuka-Kerliu; Gordana Petrusevska; Halit Maloku; Vjollca Sahatciu-Meka; Sadushe Loxha; Naim Loxha; Labinot Shahini
Journal:  J Med Case Rep       Date:  2010-02-18

Review 2.  Pancreatic endocrine neoplasms: a current update on genetics and imaging.

Authors:  S Philips; S N Shah; R Vikram; S Verma; A K P Shanbhogue; S R Prasad
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

3.  Secondary malignancy in patients with sporadic neuroendocrine neoplasia.

Authors:  M Krausch; A Raffel; M Anlauf; M Schott; N Lehwald; A Krieg; F Kröpil; K Cupisti; W T Knoefel
Journal:  Endocrine       Date:  2013-03-14       Impact factor: 3.633

4.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

Review 5.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

6.  "Cherry picking", a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours.

Authors:  Markus Krausch; Andreas Raffel; Martin Anlauf; Matthias Schott; Nadja Lehwald; Andreas Krieg; Stefan Andreas Topp; Kenko Cupisti; Wolfram Trudo Knoefel
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

Review 7.  Ghrelin in neuroendocrine organs and tumours.

Authors:  Chrysanthia A Leontiou; Giulia Franchi; Márta Korbonits
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 8.  Gl-NETs-uniform but also diverse.

Authors:  Yogeshwar Dayal
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

9.  Histopathology of gastrointestinal neuroendocrine neoplasms.

Authors:  Kenichi Hirabayashi; Giuseppe Zamboni; Takayuki Nishi; Akira Tanaka; Hiroshi Kajiwara; Naoya Nakamura
Journal:  Front Oncol       Date:  2013-01-22       Impact factor: 6.244

Review 10.  Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors.

Authors:  Irina A Lubensky; Zhengping Zhuang
Journal:  Endocr Pathol       Date:  2007       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.